KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Operating Expenses (2020 - 2023)

AbCellera Biologics' Operating Expenses history spans 4 years, with the latest figure at $75.2 million for Q4 2023.

  • For the quarter ending Q4 2023, Operating Expenses rose 26.82% year-over-year to $75.2 million, compared with a TTM value of $75.2 million through Sep 2024, down 70.99%, and an annual FY2024 reading of $343.6 million, up 24.84% over the prior year.
  • Operating Expenses for Q4 2023 was $75.2 million at AbCellera Biologics, up from $61.5 million in the prior quarter.
  • The five-year high for Operating Expenses was $91.6 million in Q1 2022, with the low at $6.8 million in Q1 2020.
  • Average Operating Expenses over 4 years is $49.5 million, with a median of $56.0 million recorded in 2021.
  • Year-over-year, Operating Expenses skyrocketed 558.9% in 2021 and then fell 15.9% in 2023.
  • Tracing ABCL's Operating Expenses over 4 years: stood at $47.1 million in 2020, then rose by 22.59% to $57.8 million in 2021, then increased by 2.67% to $59.3 million in 2022, then increased by 26.82% to $75.2 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Operating Expenses are $75.2 million (Q4 2023), $61.5 million (Q3 2023), and $61.4 million (Q2 2023).